HUIXIAN TANG: Open Payments
NPI 1831920768 · YUKON, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$618 in 37 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $54 · 2025 $618
Food & beverage: $618
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 14 | $220 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $111 |
| Novo Nordisk Inc | 4 | $60 |
| ABBVIE INC. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $33 |
| Astellas Pharma US Inc | 2 | $30 |
| Exact Sciences Corporation | 2 | $29 |
| Sage Therapeutics, LLC | 1 | $27 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
Products named: JARDIANCE, MOUNJARO, Ozempic, VRAYLAR, CAPLYTA, Veozah, ZURZUVAE, LEQVIO.
Industry payments across OK — which companies pay providers there.
